ResMed (FRA:RMEA) Cyclically Adjusted Revenue per Share: €2.35 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RMEA ResMed Inc FRA:RMEA
90 GF Score
Price €17.60
GF Value €22.89
! 1 Warning Sign
View Full Analysis

What is ResMed Cyclically Adjusted Revenue per Share?

ResMed FRA:RMEA -1.68% 90 Cyclically Adjusted Revenue per Share is €2.35 as of Mar. 2026. GuruFocus rates FRA:RMEA with a GF Score™ of 90/100 and a GF Value™ of €22.89. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ResMed's adjusted revenue per share for the three months ended in Mar. 2026 was €0.850. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.35 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ResMed's average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ResMed was 26.90% per year. The lowest was 11.20% per year. And the median was 14.30% per year.

As of today (2026-08-03), ResMed's current stock price is €17.60. ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €2.35. ResMed's Cyclically Adjusted PS Ratio of today is 7.49.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ResMed was 18.37. The lowest was 6.15. And the median was 9.72.


ResMed  (FRA:RMEA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ResMed's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.60/2.35
=7.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ResMed was 18.37. The lowest was 6.15. And the median was 9.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ResMed Cyclically Adjusted Revenue per Share Related Terms


ResMed Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ResMed's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Cyclically Adjusted Revenue per Share Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.33 1.80 1.90 2.18 2.18

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.26 2.18 2.22 2.34 2.35

FRA:RMEA vs MDLN, WST, COO: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted PS Ratio falls into.


FRA:RMEA
90GF Score
ResMed Inc FRA:RMEA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.85/330.2130*330.2130
=0.850

Current CPI (Mar. 2026) = 330.2130.

ResMed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.326 241.018 0.447
201609 0.292 241.428 0.399
201612 0.354 241.432 0.484
201703 0.337 243.801 0.456
201706 0.347 244.955 0.468
201709 0.306 246.819 0.409
201712 0.353 246.524 0.473
201803 0.333 249.554 0.441
201806 0.370 251.989 0.485
201809 0.350 252.439 0.458
201812 0.396 251.233 0.520
201903 0.406 254.202 0.527
201906 0.431 256.143 0.556
201909 0.426 256.759 0.548
201912 0.455 256.974 0.585
202003 0.478 258.115 0.612
202006 0.468 257.797 0.599
202009 0.437 260.280 0.554
202012 0.449 260.474 0.569
202103 0.444 264.877 0.554
202106 0.496 271.696 0.603
202109 0.523 274.310 0.630
202112 0.539 278.802 0.638
202203 0.534 287.504 0.613
202206 0.588 296.311 0.655
202209 0.652 296.808 0.725
202212 0.662 296.797 0.737
202303 0.708 301.836 0.775
202306 0.702 305.109 0.760
202309 0.700 307.789 0.751
202312 0.723 306.746 0.778
202403 0.747 312.332 0.790
202406 0.770 314.175 0.809
202409 0.747 315.301 0.782
202412 0.830 315.605 0.868
202503 0.812 319.799 0.838
202506 0.795 322.561 0.814
202509 0.775 324.800 0.788
202512 0.830 324.054 0.846
202603 0.850 330.213 0.850

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.35 mean?
ResMed (FRA:RMEA) has a Cyclically Adjusted Revenue per Share of €2.35 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ResMed and its competitors.
Is ResMed's Cyclically Adjusted Revenue per Share too high?
ResMed's current Cyclically Adjusted Revenue per Share is €2.35. Overall, ResMed has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does ResMed's Cyclically Adjusted Revenue per Share compare to MDLN and WST?
ResMed's Cyclically Adjusted Revenue per Share of €2.35 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ResMed and its competitors. ResMed's current Cyclically Adjusted Revenue per Share is €2.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
ResMed (FRA:RMEA) has a current Cyclically Adjusted Revenue per Share of €2.35. The stock's GF Value™ is €22.89, compared to a current price of €17.60 — trading 23.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.35. ResMed's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ResMed (FRA:RMEA), the current Cyclically Adjusted Revenue per Share is €2.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (FRA:RMEA) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of €17.60 is trading 23.1% below its estimated GF Value™ of €22.89.

Key valuation signals for FRA:RMEA:

  • Cyclically Adjusted Revenue per Share: €2.35
  • GF Value™: €22.89 vs. price of €17.60 (23.1% below fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the FRA:RMEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
90GF Score

Get the complete analysis for FRA:RMEA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.60
Price
€22.89
GF Value